PIPGEN - PhD Project 12: Treg evolution in B cell lymphoma patients under Idelalisib.

PIPGEN - PhD Project 12: Treg evolution in B cell lymphoma patients under Idelalisib.

tres logos iserm.PNG
RESEARCH PROFILE: First Stage Researcher (R1[1])

APPLICATION DEADLINE: 27 June 2021

EU RESEARCH FRAMEWORK PROGRAME: HORIZON 2020

MARIE SKOLODOWSKA CURIE GRANT AGREEMENT NUMBER: 955534

[1] First Stage Researcher (R1) PhD candidate or equivalent. Early stage researcher with less than 4 years FTE research experience.

Recuadro con fechas definitivo.png

PhD Project details

 

The PI3Kδ inhibitor, Idelalisib (IDL), is approved for chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL), but induces many toxicities. In other B-cell indolent lymphomas, clinical responses are also reported, but with fewer tolerance concerns. The reason for this high activity and fewer safety issues observed in a cohort of CLL/FL patients (treated at IUCTO) is not understood. To identify cellular mechanisms at the origin of these differential responses, ESR12 will: analyse single-cell experiments in spleen from FL or splenic marginal zone lymphoma (SMZL) patients, monitor the evolution of patient circulating immune cell population (incl. Treg) under treatment to explain activity/toxicities, investigate activity/toxicity events linked to other PI3Kδ drug and dissect molecular mechanisms linked to heterogeneity of response ex vivo.

Host: Institut national de la santé et de la recherche / Université de Toulouse III (INSERM), France.

Supervisors: Dr. Julie Guillermet-Guibert and Dr. Loïc Ysebaert.

Doctoral programme: Université Toulouse III – Paul Sabatier.

Envisioned secondments: iOnctura, ErasmusMC.

 

Or, know someone who would be a perfect fit? Let them know!

Teamtailor

Applicant tracking system by Teamtailor